GI
SLN

GAMMA Investing’s Silence Therapeutics SLN Stock Holding History

GAMMA Investing’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121K Buy
11,063
+1,698
+18% +$11.9K ﹤0.01% 1669
2026
Q1 		$49.4K Sell
9,365
-747
-7% -$4.11K ﹤0.01% 2192
2025
Q4 		$61.5K Buy
10,112
+197
+2% +$1.26K ﹤0.01% 1927
2025
Q3 		$51.5K Buy
9,915
+1,582
+19% +$8.79K ﹤0.01% 1969
2025
Q2 		$48.3K Buy
8,333
+4,773
+134% +$20.5K ﹤0.01% 1966
2025
Q1 		$10K Sell
3,560
-2,532
-42% -$12.4K ﹤0.01% 2743
2024
Q4 		$41.9K Buy
6,092
+5,233
+609% +$67.5K ﹤0.01% 1796
2024
Q3 		$15.6K Hold
859
– – ﹤0.01% 2248
2024
Q2 		$16.3K Sell
859
-17
-2% -$362 ﹤0.01% 1989
2024
Q1 		$18.9K Sell
876
-42
-5% -$913 ﹤0.01% 1688
2023
Q4 		$20.7K Buy
+918
New +$10.3K 0.01% 1484

Other funds holding SLN

CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

GAMMA Investing's SLN Position: Q2 2026 in Review

GAMMA Investing increased its Silence Therapeutics (SLN) stake by 18% in Q2 2026, buying an estimated $11.9K and bringing the position to 11,063 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #1669.

GAMMA Investing first reported a position in SLN in Q4 2023 and has held it in 11 quarters since. 4 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • GAMMA Investing held 11,063 shares of Silence Therapeutics worth $121K as of Q2 2026.
  • GAMMA Investing bought 1,698 Silence Therapeutics shares in Q2 2026, an estimated $11.9K.
  • Silence Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #1669 holding.
  • GAMMA Investing first reported a position in Silence Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 4 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.